Background Urokinase-type plasminogen activator receptor (uPAR), is a multi-functional receptor on cell surface, widely present in endothelial cells, fibroblasts, and a variety of malignant cells. Our ...
MNPR-101 is Monopar’s proprietary antibody that targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal ...
The therapy is designed to selectively attack cancer cells by focusing on the urokinase plasminogen activator receptor (uPAR), common in various tumor types. With promising clinical and ...